BioLife Solutions, Inc.
NASDAQ:BLFSMedical - Instruments & Supplies
+$0.40 today
- Market cap
- $1.89B
- Beta
- 1.97
- P/E (TTM)
- -119.9
- EPS (TTM)
- -$0.22
Volume 4.39M
Average 0.52M
BLFS Debt Repayment
Cash used to repay borrowings during the period.
BioLife Solutions, Inc.NASDAQ: BLFS
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment grows, but more slowly than its trailing trend
Q1 FY2026 debt repayment of $2.5M (cash outflow) rose 0.0% year over year, behind the +12.8% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter.
Context
- Debt repayment amounted to 10.4% of revenue in FY2025, up 2.4 pp from a year earlier.
- Debt repayment increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +12.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (10M) USD
- Year-over-year change
- -51.3%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10M) | -51.3% |
| FY2024 | 2024-12-31 | (6.61M) | -1226.9% |
| FY2023 | 2023-12-31 | (498K) | -102.8% |
| FY2022 | 2022-12-31 | 17.84M | +716.3% |
| FY2021 | 2021-12-31 | (2.89M) | — |
Debt Repayment vs competitors
How BLFS compares with its peers on the latest reported figures
- BLFS's LTM Mar 2026 debt repayment of $10M is the 6th largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +12.8% is the 4th highest of 8, against a peer median of -15.9%.
- Debt repayment amounts to 10.0% of revenue for BLFS, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $460.97M | — | +2443.9% | 68.4% | |
| LTM Apr 2026 | $75.19M | +1051.0% | — | 15.2% | |
| LTM Mar 2026 | $60.73M | +103.9% | -28.0% | 22.6% | |
| LTM Aug 2026 | $19.93M | -80.1% | +0.0% | 2.3% | |
| LTM Sep 2026 | $15.38M | -74.0% | -29.7% | 5.8% | |
| LTM Mar 2026 | $10M | +12.8% | — | 10.0% | |
| LTM Jun 2026 | $949K | -15.9% | — | 0.2% | |
| LTM Sep 2026 | $748K | -24.1% | +9.0% | 0.1% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jan 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | +100.0% | -30.7% | 0.0% | |
| Peer median (excluding BLFS) | $0 | -15.9% | -14.0% | 1.2% | |
Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.64M) | (139.81M) | (66.43M) | (20.18M) | (4.6M) |
| Depreciation & Amortization | 12.87M | 16.47M | 12.3M | 5.49M | 4.69M |
| Deferred Income Tax | (20.13M) | (5.24M) | (62K) | (64K) | 65K |
| Stock-Based Compensation | 13.96M | 25.33M | 31.67M | 30.92M | 22.99M |
| Change in Working Capital | (2.26M) | (14.91M) | 1.47M | 227K | (8.91M) |
| Accounts Receivables | (10.13M) | (10.75M) | 15.35M | (2.9M) | 264K |
| Inventory | 114K | (6.56M) | (8.55M) | 781K | (1.27M) |
| Accounts Payables | 2.02M | 414K | (8.43M) | 26K | (2.09M) |
| Other Working Capital | 5.74M | 1.99M | 3.09M | 2.32M | (5.82M) |
| Other Non-Cash Items | (1.64M) | 109.65M | 8.56M | (7.96M) | 5.87M |
| Operating Cash Flow | (4.84M) | (8.49M) | (12.5M) | 8.43M | 20.12M |
| Capital Expenditures | (8.39M) | (10.39M) | (6.38M) | (3.23M) | (9.48M) |
| Acquisitions (Net) | 1.56M | 0 | 0 | 60.39M | 23.52M |
| Purchases of Investments | (6.37M) | (53.12M) | (27.1M) | (18.42M) | (127.17M) |
| Sales of Investments | 6.37M | 8.92M | 56.17M | 21.92M | 41.59M |
| Other Investing Activities | (5.82M) | (3.54M) | (4.86M) | (2.37M) | 0 |
| Investing Cash Flow | (12.64M) | (58.12M) | 17.84M | 58.3M | (71.54M) |
| Debt Repayment | (2.89M) | 17.84M | (498K) | (6.61M) | (10M) |
| Common Stock Issued | 1.27M | 192K | 10.24M | 202K | 18K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.16M) | (1.71M) | 845K | (377K) | (942K) |
| Financing Cash Flow | (2.78M) | 16.32M | 10.59M | (6.78M) | (10.92M) |
| Effect of Forex Changes | (282K) | (108K) | 35K | 0 | 0 |
| Net Change in Cash | (20.59M) | (50.4M) | 15.97M | 59.95M | (62.35M) |
| Free Cash Flow | (13.22M) | (18.87M) | (18.88M) | 5.2M | 10.64M |
BioLife Solutions, Inc.
NASDAQ:BLFS
Intrinsic Alpha fair value
Locked
Current Price
$38.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.